Aligos Therapeutics, INC

Aligos Therapeutics stockholders approved an amendment to the 2020 Employee Stock Purchase Plan and re-elected two directors at the 2026 Annual Meeting.

Aligos Therapeutics has entered into a licensing agreement with Xiamen Amoytop Biotech for the development and commercialization of its Hepatitis B drug in China.

Aligos Therapeutics announced positive interim results from its Phase 2 B-SUPREME study for pevifoscorvir sodium in chronic Hepatitis B, alongside FDA Fast Track Designation.

Aligos Therapeutics reports significant pipeline progress and a substantial reduction in net loss for Q4 and full year 2025.

Aligos Therapeutics announced third quarter 2025 financial results and pipeline updates, highlighting progress in its Phase 2 HBV study and promising preclinical data for ALG-055009.

Aligos Therapeutics announced significant progress in its lead chronic hepatitis B program, ALG-000184, entering Phase 2, alongside reporting a net loss of $15.9 million for the second quarter of 2025.

Aligos Therapeutics reports a reduced net loss for the nine months ended September 30, 2025, driven by a significant fair value change in warrants, while advancing its lead HBV drug into Phase 2 and exploring funding options amid a going concern warning.

Aligos Therapeutics reported a net income for Q2 2025 driven by a non-cash warrant re-measurement gain, while advancing its clinical pipeline for HBV, MASH, and coronavirus with new trial initiations and positive Phase 2a data for MASH.

Aligos Therapeutics reports a net income of $43.1 million for Q1 2025, primarily due to a significant gain from the change in fair value of common warrants, while highlighting progress in its clinical development programs.

Aligos Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

Aligos Therapeutics reported a net income of $5.1 million for the second quarter of 2024, a significant shift from a net loss of $18.8 million in the same period last year, while also highlighting progress in its clinical programs.

Aligos Therapeutics, a clinical-stage biopharmaceutical company, released its first quarter 2024 financial results, highlighting progress in its MASH, CHB, and coronavirus programs.

Aligos Therapeutics reports continued pipeline advancement in HBV, MASH, and coronavirus programs, alongside significant net losses and substantial doubt about its ability to continue as a going concern.

Aligos Therapeutics, a clinical-stage biotechnology company, details its financial performance for 2024 and outlines progress in its liver disease and viral infection programs in its 10K filing.

Aligos Therapeutics, a clinical-stage biopharmaceutical company, released its 10-K filing for the fiscal year ended December 31, 2023, detailing progress in its MASH and viral disease programs and financial results.

Aligos Therapeutics Director Heather Preston acquired stock options for 5,860 shares of common stock.

Margarita Chavez, a Director at Aligos Therapeutics, Inc., acquired stock options for 5,860 shares of common stock.

Aligos Therapeutics Director Bridget A. Martell acquired stock options for 5,860 shares of common stock.

James Paul Scopa, a Director at Aligos Therapeutics, Inc., acquired stock options for 5,860 shares of common stock on June 25, 2026.

Carole Nuechterlein, a Director at Aligos Therapeutics, Inc., was granted a stock option for 5,860 shares of common stock.

Aligos Therapeutics Director Peter Hirth acquired 5,860 stock options with an exercise price of $5.50, vesting fully on the first anniversary of the grant date or before the 2027 annual meeting.

Aligos Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 25, 2026, to elect directors, ratify auditor, and vote on ESPP amendment and executive compensation.

Aligos Therapeutics will hold its annual stockholders meeting on June 25, 2025, featuring proposals for director elections, auditor ratification, and amendments to stock plans and authorized shares.

Aligos Therapeutics is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the appointment of Ernst & Young LLP as its independent accounting firm, and approve amendments to its incentive plan and corporate charter.

Aligos Therapeutics is holding its annual stockholders meeting on June 27, 2024, to vote on proposals including the election of directors, ratification of the auditor, a potential reverse stock split, and amendments to the company's certificate of incorporation and 2020 Plan.

Aligos Therapeutics is asking stockholders to approve a reverse stock split, an increase in authorized shares, and an amendment to its incentive award plan at the upcoming annual meeting.

Dr. Lawrence M. Blatt has filed an amended Schedule 13D, indicating his beneficial ownership in Aligos Therapeutics, Inc. has fallen below the 5% reporting threshold.

Woodline Partners LP has disclosed a beneficial ownership of 4.4% in Aligos Therapeutics, Inc., holding 239,362 shares, including exercisable warrants.

Sio Capital Management, LLC reported a 5.46% beneficial ownership stake in Aligos Therapeutics, Inc. as of December 31, 2025.

Woodline Partners LP has filed an amended Schedule 13G, reporting an 8.7% beneficial ownership of Aligos Therapeutics, Inc.'s common stock as of September 30, 2025.

Woodline Partners LP has disclosed a 9.8% passive ownership stake in Aligos Therapeutics, Inc., holding 518,300 shares of common stock.

Sio Capital Management, LLC has disclosed a 5.49% beneficial ownership stake in Aligos Therapeutics, Inc., holding 355,937 shares of common stock.

Adage Capital Management and its principals have filed an amended Schedule 13G, disclosing a 3.90% beneficial ownership in Aligos Therapeutics, Inc.